Next Science Limited
NXSCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $23 | $22 | $12 | $9 |
| % Growth | 2.9% | 89.4% | 30.9% | – |
| Cost of Goods Sold | $4 | $6 | $5 | $3 |
| Gross Profit | $18 | $16 | $12 | $6 |
| % Margin | 80.8% | 73.2% | 101.6% | 66.4% |
| R&D Expenses | $7 | $6 | $6 | $5 |
| G&A Expenses | $7 | $6 | $5 | $4 |
| SG&A Expenses | $23 | $26 | $16 | $12 |
| Sales & Mktg Exp. | $16 | $20 | $10 | $7 |
| Other Operating Expenses | -$1 | -$0 | $8 | -$1 |
| Operating Expenses | $29 | $32 | $30 | $15 |
| Operating Income | -$10 | -$16 | -$13 | -$9 |
| % Margin | -45.2% | -71.9% | -108.5% | -103.7% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$11 | -$16 | -$13 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$25 | -$18 | -$9 |
| % Margin | -46.4% | -110.5% | -156.2% | -100.9% |
| EPS | -0.036 | -0.07 | -0.087 | -0.048 |
| % Growth | 47.8% | 20% | -82.9% | – |
| EPS Diluted | -0.036 | -0.07 | -0.087 | -0.048 |
| Weighted Avg Shares Out | 292 | 234 | 210 | 197 |
| Weighted Avg Shares Out Dil | 292 | 234 | 210 | 197 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$9 | -$14 | -$12 | -$9 |
| % Margin | -39.6% | -65% | -100.5% | -103% |